Developing small molecule drugs to inhibit a key enzyme of the SARS-CoV-2 virus
Small Molecule Inhibitors Against 3C-Like Protease of SARS-CoV-2
['FUNDING_R01'] · KANSAS STATE UNIVERSITY · NIH-10849716
This study is looking for new medicines that can stop the SARS-CoV-2 virus, which causes COVID-19, from making copies of itself, and it's for anyone interested in better treatments for the virus.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | KANSAS STATE UNIVERSITY (nih funded) |
| Locations | 1 site (MANHATTAN, UNITED STATES) |
| Trial ID | NIH-10849716 on ClinicalTrials.gov |
What this research studies
This research focuses on creating small molecule inhibitors that target the 3C-like protease of the SARS-CoV-2 virus, which is essential for the virus's replication. The approach involves screening various compounds to identify those that can effectively inhibit this protease, thereby preventing the virus from multiplying. The research utilizes advanced techniques, including high-resolution crystal structure analysis, to understand how these inhibitors interact with the virus at a molecular level. If successful, these inhibitors could serve as antiviral treatments for COVID-19 and other related coronavirus infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are at risk of severe COVID-19 infection or those who have been diagnosed with COVID-19.
Not a fit: Patients who are not infected with SARS-CoV-2 or those who have already recovered from COVID-19 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective antiviral drugs for treating COVID-19 and potentially other coronavirus infections.
How similar studies have performed: Previous research has shown success in developing antiviral compounds targeting similar proteases in other coronaviruses, indicating a promising avenue for this approach.
Where this research is happening
MANHATTAN, UNITED STATES
- KANSAS STATE UNIVERSITY — MANHATTAN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHANG, KYEONG-OK — KANSAS STATE UNIVERSITY
- Study coordinator: CHANG, KYEONG-OK
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.